Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2025

The gastroesophageal junction adenocarcinoma therapeutics market size has grown rapidly in recent years. It will grow from $3.85 billion in 2024 to $4.48 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period was driven by the rising prevalence of *Helicobacter pylori* infection, the increasing number of Barrett’s esophagus cases, the expansion of screening programs, greater investment in research and development, and improved healthcare access.

The gastroesophageal junction adenocarcinoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $8.15 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The projected growth during the forecast period is driven by a focus on precision oncology, an increase in multidisciplinary treatment approaches, the expanding use of liquid biopsies, a shift toward minimally invasive procedures, and the rising adoption of immuno-oncology treatments. Key trends include the integration of next-generation sequencing in clinical practice, innovations in targeted radiation therapy, advancements in molecular imaging, the application of artificial intelligence in treatment planning, and improvements in surgical techniques.

The rising obesity rates are expected to drive the growth of the gastroesophageal junction adenocarcinoma (GEJA) therapeutics market. Obesity, a condition characterized by excessive body fat accumulation, is increasing due to factors such as poor dietary habits, sedentary lifestyles, lack of physical activity, and the consumption of processed and high-calorie foods. GEJA therapeutics play a crucial role in addressing the underlying mechanisms that contribute to weight gain, including inflammation, metabolic disruption, and hormonal imbalances, which can be exacerbated by the disease. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were struggling with obesity. This included 2.5 billion adults classified as overweight, with 890 million of them living with obesity. Among adults, 43% were overweight, and 16% were classified as obese. Additionally, the number of overweight children under the age of 5 reached 37 million. Therefore, the growing obesity rates are fueling the expansion of the GEJA therapeutics market.

Leading companies in the GEJA therapeutics market are focused on developing innovative combination therapies to enhance treatment efficacy, improve patient outcomes, and address resistance to existing treatments. Combination therapy involves using two or more therapeutic agents, such as drugs or treatment modalities, to improve effectiveness and target multiple aspects of a disease simultaneously. For example, in October 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for zolbetuximab-clzb in combination with fluoropyrimidine- and platinum-containing chemotherapy. Zolbetuximab-clzb is a first-in-class monoclonal antibody specifically targeting Claudin 18.2, a protein highly expressed in gastric and GEJ cancers, thereby improving treatment precision and effectiveness. By selectively binding to CLDN18.2-expressing cancer cells, this therapy enables a targeted approach, minimizing damage to healthy tissues while optimizing therapeutic outcomes.

In January 2023, Leap Therapeutics Inc., a US-based biotech company, acquired Flame Biosciences Inc. for $115 million. This acquisition strengthens Leap Therapeutics’ oncology pipeline by integrating innovative cancer therapies developed by Flame Biosciences, expanding its portfolio of targeted treatments, and advancing research efforts to develop cutting-edge solutions for GEJA and other cancers. Flame Biosciences Inc., a US-based company, specializes in developing therapeutics for gastroesophageal junction adenocarcinoma, further enhancing Leap Therapeutics' capabilities in this market.

Major players in the gastroesophageal junction adenocarcinoma therapeutics market are Pfizer Inc., F Hoffmann-La Roche AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Genentech Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., Zymeworks Inc., Zai Lab Limited, ImmunoGen Inc., Elevar Therapeutics Inc., Mirati Therapeutics Inc., Shanghai Henlius Biotech Inc., Taiho Pharmaceutical Co. Ltd., LintonPharm Ltd., Celltrion Healthcare Co. Ltd.

North America was the largest region in the gastroesophageal junction adenocarcinoma therapeutics market in 2024. The regions covered in gastroesophageal junction adenocarcinoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastroesophageal junction adenocarcinoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastroesophageal junction adenocarcinoma is a malignant tumor that forms at the junction of the esophagus and stomach, often linked to chronic acid reflux, obesity, and other risk factors. Its treatment options include targeted therapies, immunotherapy, chemotherapy, and surgical procedures designed to slow tumor progression, improve survival rates, and enhance patient outcomes.

The primary therapeutics for gastroesophageal junction adenocarcinoma include trastuzumab and ramucirumab. Trastuzumab is a targeted therapy drug used to treat HER2-positive gastroesophageal junction adenocarcinoma by blocking the HER2 protein, which contributes to cancer growth. Diagnosis is conducted through procedures such as endoscopy, X-ray, computed tomography (CT) scan, and positron emission tomography (PET) scan. Treatment approaches include esophagectomy surgery, esophageal dilation, chemotherapy, and targeted therapy. These therapeutics are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The gastroesophageal junction adenocarcinoma therapeutics market research report is one of a series of new reports that provides gastroesophageal junction adenocarcinoma therapeutics market statistics, including the gastroesophageal junction adenocarcinoma therapeutics industry global market size, regional shares, competitors with the gastroesophageal junction adenocarcinoma therapeutics market share, detailed gastroesophageal junction adenocarcinoma therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gastroesophageal junction adenocarcinoma therapeutics industry. This gastroesophageal junction adenocarcinoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastroesophageal junction adenocarcinoma therapeutics market includes revenues earned by entities by providing services such as radiation therapy, immunotherapy, surgical oncology, and palliative care and related products such as angiogenesis inhibitors, chemoradiation therapy, biosimilars, and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.